title: Allergic rhinitis: meaningful and less meaningful combination treatments including reminiscences.
abstract: Allergic rhinitis (AR) results from a complex allergen-driven mucosal inflammation in the nasal cavity. Current guideline-based therapy for allergic rhinitis include oral and nasal antihistamines, topical and systemic glucocorticoids, decongestants, antimuscarinic agents, mast cell stabilizing drugs, leukotriene-receptor antagonists, and others. In spite of guideline recommendations, most patients are using multiple therapies in an attempt to achieve symptom control. Therefore, more effective therapies for the management of AR are clearly required. Recently, a novel fixed dose combination containing azelastine and fluticasone propionate has successfully been introduced. At present, it represents the only meaningful topical drug combination. Perhaps, it will be followed by others.
authors: I
authors: I
authors: Szelenyi
mesh_terms: D000281:Administration, Intranasal; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D004338:Drug Combinations; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D014663:Nasal Decongestants / Q000008:administration & dosage / Q000627:therapeutic use; D028321:Plant Preparations / Q000627:therapeutic use; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
chemical_list: D018926:Anti-Allergic Agents; D018680:Cholinergic Antagonists; D004338:Drug Combinations; D005938:Glucocorticoids; D006633:Histamine Antagonists; D020024:Leukotriene Antagonists; D014663:Nasal Decongestants; D028321:Plant Preparations